Research Article CXCR1/CXCR2 Antagonism Is Effective in Pulmonary Defense against Klebsiella pneumoniae Infection

Copyright © 2013 Jing Wei et al.This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Klebsiella pneumoniae-associated pathology is largely mediated by neutrophilic inflammation. In this study, we administered Klebsiella pneumoniae to experimental guinea pig groups and the ELR-CXC chemokine antagonist CXCL8(3–72), ceftazidime, and dexamethasone to different groups, respectively. After 24 h, we assessed the animal’s pulmonary inflammatory levels, including gross histopathology, airway neutrophilia, lungmyeloperoxidase levels, expressions of CXCL8 and TNF, and airway bacterial loads. Comparedwith ceftazidime anddexamethasone treatments, the administration of the ELR-CXCchemokine antagonist CXCL8(3–72) alone was more effective than other methods, although it did not markedly attenuate the bacterial load. These results suggest new methods for the treatment of Klebsiella pneumoniae pathology. 1